LRMR — Larimar Therapeutics, Inc.
$2.35+3.52%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for LRMR in the TickerWise workspace.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 65
- Website: https://www.larimartx.com
Latest SEC filings for LRMR
Latest LRMR news
- Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Read article
- Larimar Therapeutics appoints John Harlow as COO Read article
- Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.